Home Biosimilar Antibodies Neuronal Signaling Beta Amyloid Aducanumab (Anti-Amyloid Beta)
For research use only. Not for use in humans.

Aducanumab (Anti-Amyloid Beta)

Synonyms: Abeta， beta-Amyloid Peptide

Aducanumab (Anti-Amyloid Beta) is a selective human monoclonal antibody targeting aggregated forms of amyloid beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research.MW :145.5 KD.

Aducanumab (Anti-Amyloid Beta)

1 Citation

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 99% Protein concentration: 5.441mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation Beta Amyloid Others
DAPT 404 Notch
RO4929097 (RG-4733) 126 γ secretase,Notch
Semagacestat (LY450139) 22 Notch
MK-0752 23
Avagacestat (BMS-708163) 22
LY2811376 19 BACE1
CRANAD-2 0
Hoechst 34580 2
Frentizole 0
Simufilam 1
Ginsenoside Rg1 7 NF-κB
Ginsenoside Re 2 NF-κB,JNK
Tabersonine hydrochloride 2
EUK 134 8
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Aducanumab (Anti-Amyloid Beta) is a selective human monoclonal antibody targeting aggregated forms of amyloid beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research.MW :145.5 KD.

Product Details

CAS No. 1384260-65-4
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05469009 ACTIVE_NOT_RECRUITING Drug: Aducanumab|Drug: Lecanemab Mild Cognitive Impairment; Alzheimer Disease 1 Ali Rezai 2022-07-14 EARLY_PHASE1
NCT05310071 TERMINATED Drug: Aducanumab|Drug: Placebo Alzheimer's Disease Biogen 2022-06-02 PHASE3
NCT04241068 TERMINATED Drug: Aducanumab Alzheimer's Disease Biogen 2020-03-02 PHASE3
NCT05108922 COMPLETED Drug: Donanemab|Drug: Aducanumab Mild Cognitive Impairment (MCI); Alzheimer Disease Eli Lilly and Company 2021-11-16 PHASE3
NCT05216887 COMPLETED Healthy Volunteer Biogen 2022-02-01 PHASE1
NCT04924140 COMPLETED Drug: Aducanumab Healthy Volunteers Biogen 2021-06-30 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-01-22)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.